Heat-treated Saccharomyces cerevisiae for antimony speciation and antimony(III) preconcentration in water samples

An analytical method was developed for antimony speciation and antimony(III) preconcentration in water samples. The method is based on the selective retention of Sb(III) by modified Saccharomyces cerevisiae in the presence of Sb(V). Heat, caustic and solvent pretreatments of the biomass were investigated to improve the kinetics and thermodynamics of Sb(III) uptake process at room temperature. Heating for 30 min at 80 degrees C was defined as the optimal treatment. Antimony accumulation by the cells was independent of pH (5-10) and ionic strength (0.01-0.1 mol L(-1)). 140 mg of yeast and 2h of contact were necessary to ensure quantitative sequestration of Sb(III) up to 750 microg L(-1). In these conditions, Sb(V) was not retained. Sb(V) was quantified in sorption supernatant by inductively coupled plasma mass spectrometry (ICP-MS) or inductively coupled plasma optical emission spectrometry (ICP-OES). Sb(III) was determined after elution with 40 mmol L(-1) thioglycolic acid at pH 10. A preconcentration factor close to nine was achieved for Sb(III) when 100mL of sample was processed. After preconcentration, the detection limits for Sb(III) and Sb(V) were 2 and 5 ng L(-1), respectively, using ICP-MS, 7 and 0.9 microg L(-1) using ICP-OES. The proposed method was successfully applied to the determination of Sb(III) and Sb(V) in spiked river and mineral water samples. The relative standard deviations (n=3) were in the 2-5% range at the tenth microg L(-1) level and less than 10% at the lowest Sb(III) and Sb(V) tested concentration (0.1 microg L(-1)). Corrected recoveries were in all cases close to 100%.     

In situ growth of nanogold on quartz crystal microbalance and its application in the interaction between heparin and antithrombin III

A novel biosensor for detecting antithrombin III (AT III) was constructed based on in situ growth of nanogold on the gold electrode of quartz crystal microbalance (QCM). The growth process of nanogold was monitored by QCM in real time. Heparin was used as the affinity ligand and immobilized onto the nanogold modified gold electrode. A flow injection analysis-quartz crystal microbalance (FIA-QCM) system was used to investigate the relationship between nanogold growth and the AT III response. Along with the nanogold particle growth within initial 5 min, the amount of heparin immobilized onto the nanogold modified electrode increased quickly. Correspondingly, the frequency response to AT III binding increased rapidly at the same time. After that, both the immobilized amount of heparin and the sensor response to AT III decreased gradually. Compared with the directly immobilized large nanogold particles, the in situ grown particles with the same size occupy more sensor surface, resulting in higher frequency shifts to AT III in the interaction study between heparin and AT III. The obtained constants of AT III binding to immobilized heparin are k(ass)=(1.65+/-0.12)x10(3) L/mols, k diss=(2.63+/-0.18)x10(-2) 1/s and K(A)=(6.27+/-0.42)x10(4) L/mol.     

Determination of MDL 201,012 at femtomole/millilitre levels in human plasma by liquid chromatography with electrochemical detection.

A sensitive and selective liquid chromatographic method to quantitate MDL 201,012 in human plasma was developed and validated. MDL 201,012 (I), diethyl-MDL 201,012 (internal standard, II) and desmethyldiol-MDL 201,012 (masking agent, III) were isolated from basified plasma (2 mL) by solid phase extraction using Bond-Elut C-18 cartridges. Endogenous components were selectively removed prior to eluting the analytes from the sorbent. Components were separated using on-line LC column switching with a cyanopropyl precolumn and a phenyl analytical column. The analytical column effluent was monitored electrochemically at a glassy carbon electrode at a potential of +1025 mV vs. Ag/AgCl. Peak-height ratios were proportional to the amount of MDL 201,012 added to plasma over the range 125-7500 pg/mL MDL 201,012. Absolute recovery of MDL 201,012 from human plasma was > 94% across the calibration range. The minimum quantitation limit was 125 pg/mL. Assay precision (%RSD) ranged from 5.2 to 13% based on the analysis of quality control standards containing 125, 250, 500, 1000, 2500, 5000 and 7500 pg/mL MDL 201,012. Corresponding assay accuracy (% relative error) was +/- 8.5%. The method has been successfully used to quantitate MDL 201,012 in samples from acute dose tolerance studies in human volunteers.     

Automated analysis of fluvoxamine in rat plasma using a column-switching system and ion-pair high-performance liquid chromatography

We have established a robust, fully automated analytical method for the analysis of fluvoxamine in rat plasma using a column-switching ion-pair high-performance chromatography system. The plasma sample was injected onto a precolumn packed with Shim-pack MAYI-ODS (50 microm), where the drug was automatically purified and enriched by on-line solid-phase extraction. After elution of the plasma proteins, the analyte was back-flushed from the precolumn and then separated isocratically on a reversed-phase C18 column (L-column ODS) with a mobile phase (acetonitrile-0.1% phosphoric acid, 36:64, v/v) containing 2 mM sodium 1-octanesulfonate. The analyte was monitored by a UV detector at a wavelength of 254 nm. The calibration line for fluvoxamine showed good linearity in the range of 5-5000 ng/mL (r > 0.999) with the limit of quantification of 5 ng/mL (RSD = 6.51%). Accuracy ranged from -2.94 to 4.82%, and the within- and between-day precision of the assay was better than 8% across the calibration range. The analytical sensitivity and accuracy of this assay is suitable for characterization of the pharmacokinetics of orally-administered fluvoxamine in rats.     

Direct analysis of the dopamine agonist (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin hydrochloride in plasma by high-performance liquid chromatography using two-dimensional column switching.

A reversed-phase, two-dimensional, liquid chromatographic method incorporating column switching and electrochemical detection was used for the direct analysis of the dopamine (D2) agonist (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin hydrochloride in plasma. Sample work-up consisted of addition of internal standard, filtration, then direct injection of the plasma sample onto an internal surface reversed-phase (ISRP) guard column where the dopamine agonist and internal standard were separated from plasma proteins. An automated pneumatic valve was then used to switch to a stronger eluent which stripped the retained substances from the ISRP support onto a C18 analytical column where the analytes were separated from endogenous biological interferences. A dual-electrode electrochemical detector was used to minimize interferences and provide the desired sensitivity. The method has a detection limit of 1.5 ng/ml and requires a total assay time of 20 min per plasma sample. The method is linear from 1.5 to 1000 ng/ml and yielded greater than 80% drug recovery for plasma concentrations greater than 10 ng/ml. Precision for the method at 100 ng/ml yielded a relative standard deviation of 4.4%. Reproducibility was within 6.5% on a 20 ng/ml spiked plasma sample assayed on different days by different people. The method has successfully been applied to human plasma samples and for pharmacokinetic studies in rats and monkeys.     

Determination of Fleroxacin in Plasma by Direct Injection High Performance Liquid Chromatography with Column Switching

ABSTRACT

A high-performance liquid chromatography (HPLC) assay was developed for the determination of fleroxacin in plasma. The plasma samples were directly introduced onto a HPLC column after filtering through a MolcutII® membrane filter, which removes high molecular weight proteins. The fleroxacin in filtrate was separated from interfering substances and retained on a pre-column using an ODS stationary phase and then was introduced to an analytical column with an ODS stationary phase by column switching. Fleroxacin and lomefloxacin, as an internal standard, were detected by ultraviolet absorbance at 295 nm. Determination of fleroxacin was possible over the concentration range 50-4000 ng/ml; the limit of detection was 20 ng/ml. The recovery of fleroxacin added to plasma was 97.3-100.4% with a coefficient of variation of less than 2.2%. This method is applicable to drug level monitoring in the plasma of patients being treated with fleroxacin and of healthy volunteers participating in pharmacokinetic studies.     

Zirconium silicate assisted removal of residual proteins after organic solvent deproteinization of human plasma,enhancing the stability of the LC–ESI-MS response for the bioanalysis of small molecules

An efficient blood plasma clean-up method was developed, where methanol protein precipitation was applied, followed by zirconium silicate assisted exclusion of residual proteins. A strong binding of zirconium (IV) silicate to the proteins enabled the elimination of remaining proteins after solvent deproteinization through a rapid solid-phase extraction (SPE) procedure. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI/TOF MS) was used for monitoring the proteins during clean-up practice applied to human plasma samples. The proteins were quantified by colorimetric detection using the bicinchoninic acid (BCA) assay. The presented analytical strategy resulted in the depletion of >99.6% proteins from human plasma samples. Furthermore, high-performance liquid chromatography hyphenated to diode-array and electrospray ionization mass spectrometric detection (HPLC–DAD/ESI MS) was applied for qualitative and quantitative analysis of the caffeoylquinic acids (CQAs) and their metabolites in human plasma. The procedure demonstrated high recoveries for the standard compounds spiked at different concentrations. Cynarin and chlorogenic acid were recovered in the range of 81–86% and 78–83%, respectively. Caffeic acid was extracted in the excess of 89–92%, while ferulic acid and dihydroxyhydrocinnamic acid showed a recovery of 87–91% and 92–95%, respectively. The method was partially validated in accordance with FDA-Industry Guidelines for Bioanalytical Method Validation (2001). The presented scheme improves the clean-up efficacy of the methanol deproteinization, significantly reduces the matrix effects and provides a great analytical tool for the isolation of small molecules from human plasma.     

Determination of phosphorus in small amounts of protein samples by ICP–MS

Inductively coupled plasma mass spectrometry (ICP-MS) is used for phosphorus determination in protein samples. A small amount of solid protein sample (down to 1 micro g) or digest (1-10 micro L) protein solution was denatured in nitric acid and hydrogen peroxide by closed-microvessel microwave digestion. Phosphorus determination was performed with an optimized analytical method using a double-focusing sector field inductively coupled plasma mass spectrometer (ICP-SFMS) and quadrupole-based ICP-MS (ICP-QMS). For quality control of phosphorus determination a certified reference material (CRM), single cell proteins (BCR 273) with a high phosphorus content of 26.8+/-0.4 mg g(-1), was analyzed. For studies on phosphorus determination in proteins while reducing the sample amount as low as possible the homogeneity of CRM BCR 273 was investigated. Relative standard deviation and measurement accuracy in ICP-QMS was within 2%, 3.5%, 11% and 12% when using CRM BCR 273 sample weights of 40 mg, 5 mg, 1 mg and 0.3 mg, respectively. The lowest possible sample weight for an accurate phosphorus analysis in protein samples by ICP-MS is discussed. The analytical method developed was applied for the analysis of homogeneous protein samples in very low amounts [1-100 micro g of solid protein sample, e.g. beta-casein or down to 1 micro L of protein or digest in solution (e.g., tau protein)]. A further reduction of the diluted protein solution volume was achieved by the application of flow injection in ICP-SFMS, which is discussed with reference to real protein digests after protein separation using 2D gel electrophoresis.The detection limits for phosphorus in biological samples were determined by ICP-SFMS down to the ng g(-1) level. The present work discusses the figure of merit for the determination of phosphorus in a small amount of protein sample with ICP-SFMS in comparison to ICP-QMS.     

Direct injection of plasma to determine pseudoephedrine by high performance liquid chromatography with column switching

An HPLC method has been developed for the determination of pseudoephedrine in plasma using column switching. Preparation of the sample was simple in that only 1000 microL of water was added to 200 microL of plasma before injection. A 900 microL aliquot was injected onto the precolumn. Double distilled water was used to elute and remove proteins and polar components in the sample. The components retained on the precolumn were flushed forward onto the analytical column by the mobile phase (acetonitrile-0.2 mol/L ammonium sulphate, 10:90 v/v) with automated column switching. The limit of determination of pseudoephedrine in plasma was 12 ng/mL. The relative standard deviations of intra- and inter-assay for the determination of pseudoephedrine in plasma were 1.2-9.8% over the concentration range 1020-21.8 ng/mL. The mean recovery by on-line solid phase extraction was 94.76% (RSD = 1.1%).     

Some characteristics of a protein-coated ODS column and its use for the determination of drugs by the direct injection analysis of plasma samples

Summary It was found that an ODS column of small pore (120?) which was coated with denatured plasma proteins (protein-coated ODS) no longer adsorbed plasma proteins from aqueous solution but retained the characteristics of native ODS for small hydrophobic molecules. Elemental analysis and nitrogen desorption (BET) analysis showed that the protein-coated ODS contained ca 25 mg proteing⁻¹ dry resin and that the pore diameter or pore volume was similar to that of native ODS. The coated denatured proteins, which seemed to be adsorbed on the external surface of the porous resin, were not eluted under usual reverse-phase elution conditions. Operating as either an analytical column or a pre-column, this protein-coated ODS column was used to analyse spiked-drugs in plasma. The recovery of all the spiked-drugs (such as doxorubicin, methotrexate) was almost quantitative (98–102%) with good reproducibilities (c.v., less than 2%). The present method was useful for the determination of total, that is, free + bound-to-plasma-proteins, hydrophobic drugs in plasma in view of its accuracy and simplicity. Presented at the 15th International Symposium on Chromatography, Nürnberg, October 1984     

Determination of total platinum in plasma and plasma ultrafiltrate,from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry

AP5280 is an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer to which are linked tetrapeptide side chains containing bioactive platinum complexes at their C-terminal sides. We have developed and validated a rapid and sensitive analytical assay for the determination of total platinum concentrations in plasma, and free platinum of an AP5280 origin in plasma ultrafiltrate (PUF), of subjects dosed with AP5280. The total platinum levels were determined by use of graphite-furnace atomic-absorption spectrometry (GF-AAS) with Zeeman correction after appropriate dilution of the plasma sample with plasma-hydrochloric acid 0.2 mol L(-1) (1:5) as diluent. The limit of quantitation of this assay is 0.25 micromol L(-1) platinum in plasma. Linear calibration curves were obtained over the concentration range 0.25-5.0 micromol L(-1). Accuracy was between 87.7% and 104.2% and precision was 15.3% at the lowest concentration and less than 14% for all other levels tested. Accuracy and precision were thus in accordance with generally accepted criteria for analytical methods. Analysis of samples obtained from patients receiving AP5280 demonstrated the applicability of the described assay.Analysis of free platinum in PUF was performed by use of a previously validated and reported assay from our institute in which the same instrumental method is used.     

Analytical artefacts in the speciation of arsenic in clinical samples

Urine and blood samples of cancer patients, treated with high doses of arsenic trioxide were analysed for arsenic species using HPLC-HGAFS and, in some cases, HPLC-ICPMS. Total arsenic was determined with either flow injection-HGAFS in urine or radiochemical neutron activation analysis in blood fractions (in serum/plasma, blood cells). The total arsenic concentrations (during prolonged, daily/weekly arsenic trioxide therapy) were in the μg mL⁻¹ range for urine and in the ng g⁻¹ range for blood fractions. The main arsenic species found in urine were As(III), MA and DMA and in blood As(V), MA and DMA.With proper sample preparation and storage of urine (no preservation agents/storage in liquid nitrogen) no analytical artefacts were observed and absence of significant amounts of alleged trivalent metabolites was proven. On the contrary, in blood samples a certain amount of arsenic can get lost in the speciation procedure what was especially noticeable for the blood cells although also plasma/serum gave rise to some disappearance of arsenic. The latter losses may be attributed to precipitation of As(III)-containing proteins/peptides during the methanol/water extraction procedure whereas the former losses were due to loss of specific As(III)-complexing proteins/peptides (e.g. cysteine, metallothionein, reduced GSH, ferritin) on the column (Hamilton PRP-X100) during the separation procedure. Contemporary analytical protocols are not able to completely avoid artefacts due to losses from the sampling to the detection stage so that it is recommended to be careful with the explanation of results, particularly regarding metabolic and pharmacokinetic interpretations, and always aim to compare the sum of species with the total arsenic concentration determined independently.     

Dependence of the rate of thrombin/antithrombin III reaction upon the turnover rate of a catalytic amount of heparin

Commercially available heparin preparations slightly enhanced the rate of thrombin/antithrombin (AT) III reaction at pH 6.05 in the absence of NaCl. However, this accelerative activity was significantly lower than that induced by heparin with high affinity for AT III (HA-heparin), probably due to the formation of the binary complexes of HA-heparin-AT III as well as that composed of thrombin and heparin with low affinity for AT III (LA-heparin). The HA-heparin-catalyzed thrombin/AT III reaction was faster in the presence of 0.1 M NaCl at pH 6.05 than that in the absence of the salt. LA-heparin and dextran sulfate (DS) were also found to accelerate the thrombin/AT III reaction rate, but neither substance catalyzed the formation of the complex in the presence of 0.1 M NaCl at pH 7.4. LA-heparin was also confirmed to compete with HA-heparin for enhancement of the thrombin/AT III reaction. Thus, it appears that AT III tends to form a ternary complex with the thrombin-DS or thrombin-LA-heparin complex, even in the presence of 0.1 M NaCl, whereas factor Xa reacts with the AT III-DS or AT III-LA-heparin complex. These results indicate that HA-heparin is the only substance having the ability to catalyze the thrombin/AT III reaction, and that its turnover rate is markedly elevated in the presence of strongly electropositive and electronegative ions because of the decreased affinity of the enzyme for heparin under such conditions.     

A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma

A simple and very precise high-performance liquid chromatographic procedure has been developed for the determination of cefmenoxime, a new broad spectrum cephalosporin antibiotic, in plasma. The workup procedure involves ultrafiltration of samples which have been treated with sodium dodecyl sulfate to displace the drug from its binding sites on plasma proteins. The ultrafiltrates are then directly injected into a high-performance liquid chromatographic system utilizing a reversed-phase analytical column, and an ultraviolet spectrophotometric detector. The mean assay coefficient of variation over a concentration range of 0.5-200 micrograms/ml is slightly greater than 1% when either p-nitrobenzoic or p-anisic acid is used as the internal standard. Recoveries of drug are essentially quantitative at all levels investigated; hence the calibration curves are rectilinear from the limit of quantification (about 0.05 microgram/ml) to at least 200 micrograms/ml.     

Controlled-pore silica glass modified with N-propylsalicylaldimine for the separation and preconcentration of trace Al(III), Ag(I) and Hg(II) in water samples.

Controlled-pore silica glass modified with N-propylsalicylaldimine (SCPSG) has been investigated as a surface-active matrix for the separation of some metal ions. The porous silica glass base was confirmed to have better stability towards hydrolysis in aqueous solution buffered at pH=9 in comparison to silica gel, which showed twice the surface area of controlled-pore silica glass. The different analytical parameters affecting the batch mode separation and preconcentration of trace Al(II), Ag(I) and Hg(II) in environmental samples using SCPSG, prior to their determination using inductively coupled plasma mass spectrometry (ICP-MS), were studied. The optimum conditions are pH 9.0 +/- 0.1, time of stirring 30 min and the eluent concentration 0.5 mol dm(-3) HNO3. The ion-exchange capacity of SCPSG with respect to Al(III), Ag(I) and Hg(II) was 0.27, 0.18 and 0.23 mmol g(-1), respectively. The recovery values for the metal ions were 96.8 +/- 0.86, 98.1 +/- 0.60 and 96.2 +/- 1.06%, and the analytical detection limits were 26.1, 1.49 and 0.44 pg cm(-3), respectively, for a preconcentration factor of 100. The method has been applied to the determination of the investigated metal ions in natural water samples as well as certified and reported samples and the results were found to be accurate.     

Fluorimetric trace determination of cerium(III) with sodium triphosphate

Sodium triphosphate acts as a specific reagent for enhancing the fluorescence intensity of cerium(III). The purpose of this study was to investigate the spectrofluorimetric determination of trace amounts of Ce(III) in sodium triphosphate solution. The excitation and emission wavelengths are 303.5 nm and 353 nm respectively. Optimum sodium triphosphate concentration is found to be 0.074 g l(-1) at room temperature. The fluorescence varies linearly with the concentration of cerium(III) in the range 0.001-45 mug ml(-1). The detection limit is 9.4 x 10(-4)mug ml(-1). The relative standard deviations for 30 mug ml(-1) and 0.05 mug ml(-1) Ce(III) in 0.074 g l(-1) sodium triphosphate solution are 1.1% and 0.72% respectively. Quenching effects of other lanthanides and some inorganic anions are described. This method is a direct and rapid analytical method for the determination of Ce(III) in rare earth mixtures and cerium concentrates.     

The preparation of sorbents for the analysis of human antithrombin III by means of high performance affinity chromatography

Summary Antithrombin III (AT III) is an anticoagulant present in blood. It is responsible among other things for blood coagulation and the wrong amount can lead to various health problems. The level of AT III can be taken as an indicator of many pathological states. Due to the very complex composition of blood, high performance affinity chromatography seems to be one of the best methods for the quantitative determination of AT III. The present paper deals with the preparation and properties of sorbents for AT III analysis. The behaviour of the chromatographic packings obtained by the bonding of heparin (used as a complementary ligand interacting with AT III) to cross-linked polysaccharide layers deposited on controlled porosity glass is discussed.     

Quantitation of atorvastatin in human plasma using directly suspended acceptor droplet in liquid-liquid-liquid microextraction and high-performance liquid chromatography-ultraviolet detection

A simple and sensitive methodology based on liquid-liquid-liquid microextraction (LLLME) followed by high-performance liquid chromatography-ultraviolet detection (HPLC-UV) has been successfully developed for the determination of atorvastatin (AT) in human plasma. AT was first extracted from 4.5 mL acidic aqueous sample (diluted plasma, donor phase, pH 1) at temperature 45 °C through 400 μL 1-octanol for 4.5 min, while being agitated by a stirring bar at 1250 rpm. Then, a 5.5 μL free suspended basic aqueous droplet (acceptor phase, pH 10) was delivered to the top-center position of the organic membrane. The mixture was stirred at 650 rpm for 7.5 min and the analyte was back-extracted into the droplet. Finally, the acceptor phase was taken into a microsyringe and injected directly into the HPLC. An enrichment factor of 187 along with substantial sample clean up was obtained under the optimized conditions. The calibration curve showed linearity in the range of 1-500 ng mL⁻¹ with regression coefficient corresponding to 0.996. Limits of detection (S/N = 3) and quantification (S/N = 10) were 0.4 and 1 ng mL⁻¹, respectively. A reasonable relative recovery (91%) and satisfactory intra-assay (4.4-7.0%, n = 6) and inter-assay (4.9-7.7%, n = 8) precision illustrated good performance of the analytical procedure. This technique was eventually applied for the determination of AT in human plasma after oral administration of 40 mg single dose of drug. The protocol proved to be highly cost-effective and reliable for the screening purpose.     

High-performance liquid chromatographic determination of cocaine and benzoylecgonine by direct injection of human blood plasma sample into an alkyl-diol-silica (ADS) precolumn

A column-switching high-performance liquid chromatographic method with UV detection for the determination of cocaine (COC) and benzoylecgonine (BZE) in human blood plasma samples is described. The method uses an alkyl-diol-silica ADS-C18 extraction precolumn. A 50- micro L plasma sample was introduced to the ADS precolumn in order to separate the analytes from proteins and endogenous compounds. The fraction containing COC and BZE was back-flushed and transferred to an Alltech mixed-mode C(18)/cation-exchange analytical column for final separation. The validation of the method revealed quantitative recoveries from 95.0 to 99.0% for COC at three different concentrations (0.5, 1.0 and 2.0 micro g mL(-1)), and from 96.0 to 99.0% for BZE at the same concentration levels with coefficients of variation <4.00% (n=5). The detection limit (signal to noise ratio (S/N)>3) was 0.03 micro g mL(-1) for all the compounds with an injection volume of 50 micro L. However, it was possible to enhance the sensitivity further by injecting larger plasma volumes, up to 200 micro L, at the same optimal conditions. The overlap of sample preparation, analysis and reconditioning of the extraction column, increase the overall sample throughput to 5 samples h(-1). The developed method has been applied to human blood plasma samples from subjects suspected of cocaine abuse.